Stock 9688 ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:23 2024-06-12 am EDT 		5-day change 1st Jan Change
15.48 HKD -2.64% Intraday chart for Zai Lab Limited +4.74% -28.00%
Jun. 11 Zai Lab Limited Announces Executive Changes, Effective June 30, 2024 CI
Jun. 04 Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA
Zai Lab's Shares Rise After Q1 Beat
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
Top Premarket Gainers
Zai Lab Q1 Loss Widens Despite Higher Revenue
Zai Lab Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. 9688 Stock
  5. News Zai Lab Limited
  6. Other languages